Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015
30 Luglio 2015 - 10:01PM
Business Wire
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that
it will report its second quarter 2015 financial results on
Thursday, August 6, 2015, before market open.
Following the announcement, management will host a conference
call and webcast at 10:00 a.m. ET that morning to discuss the
second quarter results and provide operational updates.
The conference call can be accessed by dialing (877) 407-8035
(U.S.) or (201) 689-8035 (International). For those unable to join
the live call, a replay will be available from 2:00 p.m. ET on
August 6 through 11:59 p.m. ET on August 13. To access the replay,
please dial (877) 660-6853 (U.S.) or (201) 612-7415 (International)
and refer to conference ID 13615051.
The live webcast can be accessed by visiting the Investor
Relations section of the Synta Pharmaceuticals website,
www.syntapharma.com. The webcast will also be archived under
Webcasts and Events within the Investor Relations section of the
Company's website.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile
biopharmaceutical company focused on research, development and
commercialization of novel oncology medicines that have the
potential to change the lives of cancer patients. Synta’s lead
oncology drug candidate, ganetespib, a novel heat shock protein 90
(Hsp90) inhibitor, is currently being evaluated in several clinical
trials including the pivotal GALAXY-2 Phase 3 trial in non-small
cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90
inhibitor Drug Conjugate (HDC) small molecule drug development
program. IND enabling studies have commenced for the first clinical
candidate from the HDC program, STA-12-8666, and preclinical
evaluation of additional HDC candidates is ongoing. For more
information, please visit www.syntapharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150730006562/en/
Synta Pharmaceuticals Corp.Daniel Cole,
781-541-7250dcole@syntapharma.comorArgot PartnersAndrea Rabney,
212-600-1494andrea@argotpartners.comorMedia:Argot PartnersEliza
Schleifstein, 917-763-8106eliza@argotpartners.com
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Nov 2023 a Nov 2024
Notizie in Tempo Reale relative a Synta Pharmaceuticals Corp. (MM) (NASDAQ): 0 articoli recenti
Più Synta Pharmaceuticals Corp. (MM) Articoli Notizie